Target intelligence / Profile preview

Glutamate dehydrogenase 1, mitochondrial (GDH1)

Target
GDH1
Molecular classification
Enzyme, Oxidoreductase (EC 1.4.1.3), Mitochondrial matrix protein, Homohexameric protein
01

Overview

Glutamate dehydrogenase 1 is a mitochondrial matrix enzyme encoded by the *GLUD1* gene, which catalyzes the reversible oxidative deamination of L-glutamate to α-ketoglutarate and ammonia, utilizing NAD+ or NADP+ as cofactors. It plays a critical role in nitrogen and energy metabolism, affecting glutamate flux, ammonia detoxification, and the tricarboxylic acid cycle. Allosterically regulated, GDH1 is activated by ADP and leucine and inhibited by GTP, ATP, and palmitoyl CoA. Malfunction or mutation results in metabolic diseases such as hyperinsulinism/hyperammonemia syndrome, associated with serious systemic and neurological effects. GDH1 has a hexameric structure, significant conformational flexibility, and is primarily expressed in the liver and nervous system for both metabolic and signaling functions. In research settings, polyphenolic compounds such as EGCG have been investigated as allosteric inhibitors for potential disease intervention.

Other names
Glutamate dehydrogenase 1GDH1EC 1.4.1.3mitochondrial glutamate dehydrogenaseGLUD1Glutamate dehydrogenase (NAD(P)+)Glud1 (gene symbol)
02

Mechanism of action

Allosteric inhibition (e.g., EGCG and other polyphenols block dysregulated GDH via binding at allosteric sites) Negative regulation by GTP, palmitoyl CoA, ATP Positive regulation by ADP, leucine

03

Biological functions

Oxidative deamination of L-glutamateAmmonia detoxificationEnergy metabolism (production of α-ketoglutarate for the TCA cycle)Nitrogen homeostasisInsulin homeostasisRegulation of glutamate turnover in neurotransmission
04

Disease associations

Hyperinsulinism/hyperammonemia syndrome (HHS)Neurological diseases (role in memory and brain metabolic regulation)Potential roles in neurodegeneration (GLUD2 mutations implicated in Parkinson’s disease)
05

Safety considerations

Risk of hypoglycemia due to excessive insulin releaseHyperammonemia due to increased ammonia productionPotential neurological side effects if modulated in the CNS
06

Interacting drugs

EGCG (epigallocatechin gallate, polyphenol from green tea)

1 more in the full profile.

07

Biomarkers

Elevated GDH1 activity used in diagnosis of hyperinsulinism/hyperammonemia syndromePlasma ammonia level (for HHS monitoring)Insulin level (for HHS monitoring)

Beyond the preview

Go deeper on Glutamate dehydrogenase 1, mitochondrial (GDH1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate dehydrogenase 1, mitochondrial (GDH1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call